# CytoNiche

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytoniche

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.cytoniche.com
- Total disclosed funding: $47M
- Latest round: Series B (Sep 15, 2025)
- Investors on record: 22

## About

Founded in 2018, CytoNiche is focused on the development of advanced technologies in 3D cell manufacturing. The company has not reported any significant pivots or changes in its business strategy. It is headquartered in Beijing, China, and was co-founded by Wei Liu and Xiaojun Yan, both of whom serve as its CEOs. CytoNiche has successfully raised a total of CNY 300 million, primarily through its Series B funding round on March 3, 2022, with investments from multiple entities including CICC Capital and Gaorong Capital. This funding represents the total amount raised by the company across its funding rounds. In September 2025, CytoNiche closed series B+ funding from new investors Shunxi Fund, Beijing Guorui Investment, China Reform Holdings, Zhouji Tongli Capital, CMB International Asset Management, Rongke Dingsheng Capital and Zhongguancun Venture Capital, and other investors.

CytoNiche specializes in developing a 3D cell manufacturing platform aimed at the cell and gene therapy sectors. Their core offerings include advanced technology services that facilitate scalable three-dimensional cell amplification, addressing critical manufacturing challenges. The company serves biopharmaceutical firms and research institutions, with a focus on innovative treatment modalities, and markets its products in North America, Europe, and Asia.

CytoNiche operates a revenue model based on providing specialized technical services to the biopharmaceutical industry. Their transactions primarily involve B2B partnerships where companies contract CytoNiche for expertise in 3D cell manufacturing processes, leading to tailored service agreements that meet specific therapeutic goals.

The series B+ financing will be used in deepening the technical research and development of cell production systems, expanding the product matrix, and upgrading the overall solution for large-scale expansion covering the entire life cycle of cell drugs.

## Funding rounds

- Series B, Sep 15, 2025 — Zhongguancun Venture Capital, CMB International Asset Management, China Reform Holdings, Zhouji Tongli Capital, Beijing Guorui Investment, Shunxi Fund, Rongke Dingsheng Capital
- Series B, Mar 3, 2022, $47M — Detong Capital, China International Capital Corporation, Shanghai Jianyi Private Equity Fund Management, Sinovac Biotech Co. Ltd., Gaorong Ventures, Hongtai Aplus, 3E Bioventures Capital, Yijing Investment, Yuanhui Investment, Suzhou Qingfen Capital Management
- Series A, Apr 28, 2021 — 3E Bioventures Capital
- Series A, Sep 3, 2020 — Detong Capital, Beijing Capital Science and Technology Development Group Investment Management
- Series A, Jan 1, 2019 — CASH Capital, T-Capital, Tsinghua Technology Transfer Fund, C&I Capital

## Investors

- CASH Capital (https://capitalatlas.ai/funds/cash-capital) — Series A
- T-Capital — Series A
- Tsinghua Technology Transfer Fund (https://capitalatlas.ai/funds/tsinghua-technology-transfer-fund) — Series A
- C&I Capital (https://capitalatlas.ai/funds/c-i-capital) — Series A
- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series A, Series B
- Beijing Capital Science and Technology Development Group Investment Management (https://capitalatlas.ai/funds/beijing-capital-science-and-technology-development-group-inv) — Series A
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A, Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series B
- Sinovac Biotech Co. Ltd. — Series B
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series B
- Hongtai Aplus (https://capitalatlas.ai/funds/hongtai-aplus) — Series B
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series B
- Yuanhui Investment — Series B
- Suzhou Qingfen Capital Management — Series B
- Zhongguancun Venture Capital (https://capitalatlas.ai/funds/zhongguancun-venture-capital) — Series B
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series B
- China Reform Holdings (https://capitalatlas.ai/funds/china-reform-holdings) — Series B
- Zhouji Tongli Capital (https://capitalatlas.ai/funds/zhouji-tongli-capital) — Series B
- Beijing Guorui Investment — Series B
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series B
- Rongke Dingsheng Capital (https://capitalatlas.ai/funds/rongke-dingsheng-capital) — Series B